🔎 Trials Near Me

Home › Chronic Lymphocytic Leukemia › Mississippi

Pag-aaral pangklinika para sa Chronic Lymphocytic Leukemia sa Mississippi

5 pag-aaral para sa Chronic Lymphocytic Leukemia ang naghahanap ng mga kalahok sa mga site sa Mississippi.

Opisyal na teksto ng pag-aaral (English)

Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL

  • Baptist Memorial Hospital and Cancer Center-Desoto, Southhaven
Nagre-recruitPhase 3
Edad 65 pataas · Lahat ng kasarian · Na-update Okt 2, 2026 · NCT07321652

Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study

  • Baptist Memorial Hospital and Cancer Center-Golden Triangle, Columbus
  • Baptist Cancer Center-Grenada, Grenada
  • Baptist Memorial Hospital and Cancer Center-Union County, New Albany
  • at 2 pa
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Set 30, 2026 · NCT04269902

A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).

  • Hattiesburg Clinic Hematology/Oncology ( Site 5416), Hattiesburg
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Set 24, 2026 · NCT05947851

A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

  • Gulfport Memorial Hospital, Gulfport
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update May 19, 2026 · NCT06588478

Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL)

  • Hattiesburg Clinic /ID# 233443, Hattiesburg
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Peb 9, 2026 · NCT04895436

Mula sa ClinicalTrials.gov, na-kuha noong Okt 5, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.